BETA 2 GLYCOPROTEIN 1 IGG

The Beta 2 Glycoprotein 1 (β2GP1) IgG Antibody Test is a specialized blood test that detects Immunoglobulin G (IgG) autoantibodies against Beta 2 Glycoprotein 1 (β2GP1), an important plasma protein involved in regulating blood clotting. This test is one of the primary laboratory tests recommended for diagnosing Antiphospholipid Syndrome (APS), an autoimmune disorder characterized by an increased risk of abnormal blood clot formation and pregnancy-related complications.

Antiphospholipid Syndrome occurs when the immune system mistakenly produces antibodies against phospholipid-binding proteins such as Beta 2 Glycoprotein 1. These antibodies interfere with normal blood clotting mechanisms, increasing the likelihood of deep vein thrombosis (DVT), pulmonary embolism, stroke, heart attack, and recurrent pregnancy loss.

Among the three antibody classes (IgG, IgM, and IgA), Beta 2 Glycoprotein 1 IgG antibodies are considered one of the most clinically significant markers for APS and are included in the internationally accepted laboratory classification criteria for the diagnosis of Antiphospholipid Syndrome.

The Beta 2 Glycoprotein 1 IgG Antibody Test is usually performed together with Beta 2 Glycoprotein 1 IgM, Anticardiolipin (IgG and IgM) antibodies, and Lupus Anticoagulant testing to provide a comprehensive evaluation of autoimmune clotting disorders.

Benefits of the Test

• Detects Beta 2 Glycoprotein 1 IgG autoantibodies
• Helps diagnose Antiphospholipid Syndrome (APS)
• Assists in evaluating autoimmune clotting disorders
• Supports investigation of unexplained thrombosis
• Helps assess recurrent pregnancy loss
• Forms part of the international APS diagnostic criteria
• Requires only a peripheral blood sample

Why Doctors Recommend This Test

Doctors may recommend this test for individuals with:

• Deep vein thrombosis (DVT)
• Pulmonary embolism
• Stroke or transient ischemic attack (TIA) at a young age
• Recurrent miscarriages
• Stillbirth or unexplained fetal loss
• Severe pre-eclampsia
• Unexplained blood clotting disorders
• Systemic Lupus Erythematosus (SLE)
• Suspected Antiphospholipid Syndrome

Preparation Before Test

Sample Required

• Peripheral venous blood sample (Serum)

Preparation Guidelines

• No fasting is generally required.
• Continue medications unless advised otherwise by your physician.
• Inform your healthcare provider about anticoagulant therapy, pregnancy history, autoimmune disorders, or previous blood clots.
• Follow laboratory instructions before sample collection.

Reporting Time

Results are generally available within 3–7 working days, depending on laboratory methodology.

Who Should Take This Test?

This test is recommended for:

• Individuals with suspected Antiphospholipid Syndrome (APS)
• Patients with unexplained venous or arterial thrombosis
• Women with recurrent miscarriages or pregnancy complications
• Patients with Systemic Lupus Erythematosus (SLE)
• Individuals with autoimmune disorders associated with thrombosis
• Patients referred by rheumatologists, hematologists, obstetricians, or physicians

Clinical Significance

A positive Beta 2 Glycoprotein 1 (β2GP1) IgG antibody result may indicate:

• Antiphospholipid Syndrome (APS)
• Autoimmune Thrombotic Disorder
• Increased Risk of Venous Thrombosis
• Increased Risk of Arterial Thrombosis
• Pregnancy-Related Complications

Common clinical features associated with APS include:

• Deep vein thrombosis (DVT)
• Pulmonary embolism
• Stroke or transient ischemic attack (TIA)
• Heart attack in young individuals
• Recurrent miscarriages
• Stillbirth
• Pre-eclampsia
• Low platelet count (thrombocytopenia)
• Livedo reticularis

A positive Beta 2 Glycoprotein 1 IgG result should always be interpreted together with clinical findings and other antiphospholipid antibody tests. According to international guidelines, persistent antibody positivity on two occasions at least 12 weeks apart, along with compatible clinical findings, supports the diagnosis of Antiphospholipid Syndrome.